• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨髓增生异常综合征患者红细胞输血依赖与负担的相关性:系统文献回顾和荟萃分析。

Association between red blood cell transfusion dependence and burden in patients with myelodysplastic syndromes: A systematic literature review and meta-analysis.

机构信息

Kantar, Health Division, São Paulo, Brazil.

Department of Haematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany.

出版信息

Eur J Haematol. 2021 Jul;107(1):3-23. doi: 10.1111/ejh.13619. Epub 2021 Apr 14.

DOI:10.1111/ejh.13619
PMID:33715214
Abstract

Myelodysplastic syndromes (MDS) are a group of malignant hematologic diseases characterized by ineffective hematopoiesis, which may lead to chronic anemia and transfusion dependency, with up to 30% of patients progressing to acute myeloid leukemia (AML). Studies suggest transfusion dependency may impact overall survival (OS); however, there is a lack of evidence concerning the association between transfusion status (TS) and OS in patients with MDS who become transfusion independent (TI) after treatment. In addition, the holistic impact of TS on other clinical, economic, and humanistic outcomes has not been well understood. We conducted a systematic literature review (SLR) to understand this impact. Ten studies were included and showed consistent decrease in OS in transfusion dependent (TD) compared with TI patients. These findings were confirmed by a meta-analysis (MA) reporting better OS prognosis for TI patients. A second SLR was conducted to understand the association between TS and other clinical, economic, and humanistic outcomes. Twenty-eight studies were included and showed better prognosis for other outcomes, including AML progression and leukemia-free survival for TI patients. Risk of AML progression and cumulative non-leukemic death assessed by the MA showed a trend toward worse prognosis and higher risk of AML progression for TD patients. Lower healthcare resource utilization, better quality of life, and reduced non-leukemic death for TI patients were observed. Studies not eligible for MA also showed better clinical, economic, and humanistic outcomes for TI patients. These findings contribute to understanding the association between transfusion dependence and OS among other outcomes in patients with MDS.

摘要

骨髓增生异常综合征(MDS)是一组恶性血液病,其特征为无效造血,可能导致慢性贫血和依赖输血,多达 30%的患者进展为急性髓系白血病(AML)。研究表明,输血依赖可能会影响总生存期(OS);然而,在 MDS 患者经治疗后摆脱输血依赖(TI)的情况下,输血状态(TS)与 OS 之间的关联缺乏证据。此外,TS 对其他临床、经济和人文结局的整体影响尚未得到充分理解。我们进行了一项系统文献回顾(SLR)以了解这种影响。纳入了 10 项研究,结果显示与 TI 患者相比,依赖输血(TD)患者的 OS 明显下降。荟萃分析(MA)报告 TI 患者的 OS 预后更好,证实了这一发现。为了了解 TS 与其他临床、经济和人文结局之间的关系,进行了第二次 SLR。纳入了 28 项研究,结果显示 TI 患者在其他结局方面预后更好,包括 AML 进展和无白血病生存期。MA 评估的 AML 进展和累积非白血病死亡风险显示 TD 患者的预后较差,AML 进展风险更高。TI 患者的医疗资源利用率较低、生活质量较好和非白血病死亡率降低。不符合 MA 纳入标准的研究也显示 TI 患者具有更好的临床、经济和人文结局。这些发现有助于理解 MDS 患者中输血依赖与 OS 等其他结局之间的关联。

相似文献

1
Association between red blood cell transfusion dependence and burden in patients with myelodysplastic syndromes: A systematic literature review and meta-analysis.骨髓增生异常综合征患者红细胞输血依赖与负担的相关性:系统文献回顾和荟萃分析。
Eur J Haematol. 2021 Jul;107(1):3-23. doi: 10.1111/ejh.13619. Epub 2021 Apr 14.
2
Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.红细胞输血依赖和高铁蛋白血症与骨髓增生异常综合征患者的生存受损相关:来自波兰 MDS-PALG 登记处的首个研究结果。
Adv Clin Exp Med. 2016 Jul-Aug;25(4):633-41. doi: 10.17219/acem/62397.
3
Association between transfusion status and clinical and economic outcomes in patients with myelodysplastic syndromes from the physicians' perspective.从医生角度来看输血状况与骨髓增生异常综合征患者临床结局和经济结局的关系。
Cancer Rep (Hoboken). 2023 Jan;6(1):e1680. doi: 10.1002/cnr2.1680. Epub 2022 Aug 9.
4
Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence.在出现输血依赖之前,对伴有del(5q)的低危和中危-1国际预后评分系统风险的骨髓增生异常综合征进行早期来那度胺治疗。
Cancer Med. 2015 Dec;4(12):1789-97. doi: 10.1002/cam4.523. Epub 2015 Sep 17.
5
Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study).阿扎胞苷治疗骨髓增生异常综合征、急性髓系白血病和慢性粒单核细胞白血病患者的疗效与体能状态和输血依赖性的关系(PIAZA 研究)。
Eur J Haematol. 2018 Dec;101(6):766-773. doi: 10.1111/ejh.13160. Epub 2018 Oct 25.
6
Red blood cell alloimmunization in 184 patients with myeloid neoplasms treated with azacitidine - A retrospective single center experience.184例接受阿扎胞苷治疗的骨髓肿瘤患者的红细胞同种免疫——一项单中心回顾性研究经验
Leuk Res. 2017 Aug;59:12-19. doi: 10.1016/j.leukres.2017.05.006. Epub 2017 May 9.
7
CircZBTB46 predicts poor prognosis and promotes disease progression of myelodysplastic syndromes and acute myeloid leukemia.环状 RNA ZBTB46 预测骨髓增生异常综合征和急性髓系白血病的不良预后并促进疾病进展。
Clin Exp Med. 2023 Dec;23(8):4649-4664. doi: 10.1007/s10238-023-01243-6. Epub 2023 Nov 6.
8
Red blood cell transfusion burden in myelodysplastic syndromes (MDS) with ring Sideroblasts (RS): A retrospective multicenter study by the Groupe Francophone des Myélodysplasies (GFM).环形铁幼粒细胞骨髓增生异常综合征(MDS)的红细胞输血负担:法国骨髓增生异常综合征研究组(GFM)的一项回顾性多中心研究。
Transfusion. 2022 May;62(5):961-973. doi: 10.1111/trf.16884. Epub 2022 Apr 22.
9
Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions.铁螯合疗法在骨髓增生异常综合征中的血液学改善:临床数据、潜在机制和悬而未决的问题。
Crit Rev Oncol Hematol. 2019 Sep;141:54-72. doi: 10.1016/j.critrevonc.2019.06.002. Epub 2019 Jun 10.
10
Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.来那度胺不会增加低危或中危-1 级伴 5q- 缺失骨髓增生异常综合征且依赖红细胞输注患者的 AML 进展风险:一项对比分析。
Leukemia. 2013 Apr;27(5):1072-9. doi: 10.1038/leu.2012.369. Epub 2012 Dec 21.

引用本文的文献

1
Comparative Analysis of IPSS, IPSS-R, and WPSS for Predicting Survival and Leukemic Transformation in Myelodysplastic Neoplasms: A Real-World Single-Center Experience.国际前列腺症状评分(IPSS)、修订版国际前列腺症状评分(IPSS-R)和世界卫生组织前列腺症状评分(WPSS)预测骨髓增生异常综合征生存和白血病转化的比较分析:一项单中心真实世界研究。
J Clin Med. 2025 Aug 14;14(16):5757. doi: 10.3390/jcm14165757.
2
Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial.在COMMANDS试验中,对于未使用过促红细胞生成素、低风险的骨髓增生异常综合征患者,卢司帕西普与阿法依泊汀实现长期输血独立的比较
Adv Ther. 2025 May 16. doi: 10.1007/s12325-025-03208-5.
3
Effect of add-on therapy with Traditional Chinese Medicine on the survival of patients with anemic lower-risk myelodysplastic syndromes in the real-world setting: a retrospective study.
在真实世界中,中药辅助治疗对贫血性低危骨髓增生异常综合征患者生存的影响:一项回顾性研究。
J Tradit Chin Med. 2025 Feb;45(1):152-159. doi: 10.19852/j.cnki.jtcm.2025.01.014.
4
Imetelstat for anemia in lower-risk myelodysplastic syndromes: A summary from the Institute for Clinical and Economic Review's California Technology Assessment Forum.艾美司他用于低危骨髓增生异常综合征贫血:来自临床与经济审评学会加利福尼亚技术评估论坛的总结
J Manag Care Spec Pharm. 2024 Dec;30(12):1479-1485. doi: 10.18553/jmcp.2024.30.12.1479.
5
Ivosidenib in Chinese patients with relapsed or refractory isocitrate dehydrogenase 1 mutated acute myeloid leukemia: a registry study.ivosidenib治疗复发或难治性异柠檬酸脱氢酶1突变型急性髓系白血病中国患者的一项注册研究
Blood Sci. 2024 Jun 20;6(3):e00196. doi: 10.1097/BS9.0000000000000196. eCollection 2024 Jul.
6
A Systematic Literature Review of Predictors of Erythropoiesis-Stimulating Agent Failure in Lower-Risk Myelodysplastic Syndromes.低危骨髓增生异常综合征中促红细胞生成素刺激剂失效预测因素的系统文献综述
J Clin Med. 2024 May 4;13(9):2702. doi: 10.3390/jcm13092702.
7
Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study.MEDALIST 研究中低危 MDS 患者的亚分析:继续使用芦曲泊帕治疗的获益改善。
Ann Hematol. 2023 Feb;102(2):311-321. doi: 10.1007/s00277-022-05071-8. Epub 2023 Jan 13.
8
The Proliferation Index of Erythroid Cells Predicts the Development of Transfusion-dependence in Myelodysplastic Syndrome Patients With Mildly Reduced Hemoglobin Levels at Initial Diagnosis.红系细胞增殖指数可预测初诊时血红蛋白水平轻度降低的骨髓增生异常综合征患者输血依赖的发生。
Hemasphere. 2022 Nov 9;6(12):e804. doi: 10.1097/HS9.0000000000000804. eCollection 2022 Dec.
9
The Analysis of the Effect of Blood Transfusion on Changes of Blood Platelet Parameters in Patients with Leukemia Treated with Chemotherapy.输血对化疗治疗白血病患者血小板参数变化的影响分析
Evid Based Complement Alternat Med. 2022 Aug 29;2022:2901993. doi: 10.1155/2022/2901993. eCollection 2022.
10
Patterns of transfusion burden in an unselected population of patients with myelodysplastic syndromes: A population-based study.骨髓增生异常综合征患者未选择人群的输血负担模式:基于人群的研究。
Transfusion. 2021 Oct;61(10):2877-2884. doi: 10.1111/trf.16631. Epub 2021 Sep 3.